An integrated transcriptome analysis in T-cell acute lymphoblastic leukemia links DNA methylation subgroups to dysregulated <i>TAL1</i> and ANTP homeobox gene expression by Haider, Zahra et al.
u n i ve r s i t y  o f  co pe n h ag e n  
An integrated transcriptome analysis in T-cell acute lymphoblastic leukemia links DNA
methylation subgroups to dysregulated TAL1 and ANTP homeobox gene expression
Haider, Zahra; Larsson, Pär; Landfors, Mattias; Köhn, Linda; Schmiegelow, Kjeld; Flaegstad,
Trond; Kanerva, Jukka; Heyman, Mats; Hultdin, Magnus; Degerman, Sofie
Published in:
Cancer Medicine
DOI:
10.1002/cam4.1917
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Haider, Z., Larsson, P., Landfors, M., Köhn, L., Schmiegelow, K., Flaegstad, T., ... Degerman, S. (2019). An
integrated transcriptome analysis in T-cell acute lymphoblastic leukemia links DNA methylation subgroups to
dysregulated TAL1 and ANTP homeobox gene expression. Cancer Medicine, 8(1), 311-324.
https://doi.org/10.1002/cam4.1917
Download date: 14. maj. 2020
Cancer Medicine. 2019;8:311–324.    |  311wileyonlinelibrary.com/journal/cam4
Received: 10 September 2018 | Revised: 12 November 2018 | Accepted: 19 November 2018
DOI: 10.1002/cam4.1917
O R I G I N A L  R E S E A R C H
An integrated transcriptome analysis in T‐cell acute 
lymphoblastic leukemia links DNA methylation subgroups to 
dysregulated TAL1 and ANTP homeobox gene expression
Zahra Haider1 | Pär Larsson1 | Mattias Landfors1 | Linda Köhn2 |  
Kjeld Schmiegelow3 | Trond Flægstad4 | Jukka Kanerva5 | Mats Heyman6 |  
Magnus Hultdin1 | Sofie Degerman1
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
1Department of Medical Biosciences, Umeå 
University, Umeå, Sweden
2Department of Radiation Sciences, Umeå 
University, Umeå, Sweden
3Department of Paediatrics and Adolescent 
Medicine, Rigshospitalet, Copenhagen, 
Denmark
4Department of Pediatrics, University of 
Tromsø and University Hospital of North 
Norway, Tromsø, Norway
5Children’s Hospital, Helsinki University 
Central Hospital, University of Helsinki, 
Helsinki, Finland
6Department of Women’s and Children’s 
Health, Karolinska Institutet, Stockholm, 
Sweden
Correspondence
Sofie Degerman, Medical Biosciences, 
Pathology, Umeå University, Umeå, 
Sweden.
Email: sofie.degerman@umu.se
Funding information
Umeå Universitet; Kempestiftelserna; 
Swedish Childhood Cancer Foundation; 
Medical Faculty of Umeå University; 
Lion's Cancer Research Foundation; Umeå 
Pediatric Clinic Research Foundation; 
Uppsala‐Umeå Comprehensive Cancer 
Consortium; Västerbotten County Council 
on cooperation in the field of Medicine, 
Odontology and Health; Swedish Research 
Council; Knut and Alice Wallenberg 
Foundation
Abstract
Classification of pediatric T‐cell acute lymphoblastic leukemia (T‐ALL) patients 
into CIMP (CpG Island Methylator Phenotype) subgroups has the potential to im-
prove current risk stratification. To investigate the biology behind these CIMP sub-
groups, diagnostic samples from Nordic pediatric T‐ALL patients were characterized 
by genome‐wide methylation arrays, followed by targeted exome sequencing, tel-
omere length measurement, and RNA sequencing. The CIMP subgroups did not cor-
relate significantly with variations in epigenetic regulators. However, the CIMP+ 
subgroup, associated with better prognosis, showed indicators of longer replicative 
history, including shorter telomere length (P = 0.015) and older epigenetic 
(P < 0.001) and mitotic age (P < 0.001). Moreover, the CIMP+ subgroup had sig-
nificantly higher expression of ANTP homeobox oncogenes, namely TLX3, HOXA9, 
HOXA10, and NKX2‐1, and novel genes in T‐ALL biology including PLCB4, 
PLXND1, and MYO18B. The CIMP− subgroup, with worse prognosis, was associ-
ated with higher expression of TAL1 along with frequent STIL‐TAL1 fusions (2/40 
in CIMP+ vs 11/24 in CIMP−), as well as stronger expression of BEX1. Altogether, 
our findings suggest different routes for leukemogenic transformation in the T‐ALL 
CIMP subgroups, indicated by different replicative histories and distinct methylomic 
and transcriptomic profiles. These novel findings can lead to new therapeutic 
strategies.
K E Y W O R D S
BEX1, DNA methylation, HOXA, pediatric acute lymphoblastic leukemia, TAL1
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1 |  INTRODUCTION
Acute lymphoblastic leukemia (ALL) accounts for 75%‐80% 
of all pediatric leukemia cases and is characterized by ac-
cumulation of undifferentiated blast cells in the bone mar-
row. Among the pediatric ALL cases, 15%‐20% are derived 
from the T‐cell progenitors and are classified as T‐cell ALL 
(T‐ALL).1
Recurrent molecular events associated specifically with 
T‐ALL have been identified, including activating mutations 
of NOTCH1, suppressive alterations of cell cycle regulators 
(9p21.3 deletions),2 chromosomal rearrangements involving 
the T‐cell receptor loci,3 and ectopic expression of specific 
transcription factor oncogenes.4-6 These driver oncogenes 
include the basic helix‐loop‐helix (bHLH) family mem-
bers TAL1 and LYL1; members of the HOXA and NK‐like 
(NKL) subclass of the ANTP homeobox gene family TLX1, 
TLX3, HOXA9, HOXA10, and NKX2‐1; and the LIM‐only 
domain (LMO) gene members LMO1 and LMO2. However, 
a prognostic or therapeutic relevance of these genetic alter-
ations has not been clearly demonstrated. Therefore, due to 
a lack of treatment stratifying markers, T‐ALL patients are 
currently only stratified based on their response to therapy, 
potentially overlooking important molecular prognostic in-
formation. DNA methylation alterations have been associ-
ated with prognosis in various hematological disorders.7,8 
We have previously shown, in two independent cohorts, 
prognostically relevant subgrouping of pediatric T‐ALL 
samples at diagnosis based on a CIMP (CpG island meth-
ylator phenotype) panel including 1293 gene promoter en-
riched CpG sites.9,10 In both cohorts, the CIMP− subgroup, 
with a methylation profile closer to normal T cells, had a 
worse prognosis than the CIMP+ subgroup (36% vs 86% 
5‐year event‐free survival in the NOPHO ALL 1992/2000 
treated cohort and 29% vs 6% 3‐year cumulative incidence 
of relapse in the NOPHO ALL 2008 treated cohort).9,10 
The prognostic relevance was further strengthened in the 
NOPHO ALL 2008 treated cohort by combining CIMP 
status with minimal residual disease (MRD) status at the 
end of the induction therapy, which allowed subgrouping 
of high‐risk T‐ALL patients (MRD > 0.1% at day 29) (3‐
year cumulative incidence of relapse in the MRD > 0.1%/
CIMP− subgroup was 50% vs 12% in the MRD>0.1%/
CIMP+ subgroup).9
The current study was aimed at investigating the biology 
behind the distinct T‐ALL CIMP subgroups. Integrated meth-
ylomic, genomic, and transcriptomic analysis of CIMP clas-
sified diagnostic T‐ALL samples was performed by Illumina 
HumMeth450K arrays, targeted exome sequencing, and RNA 
sequencing. The CIMP subgroups showed diverse transcrip-
tomic profiles and different replicative histories, suggesting 
that the subgroups may be associated with disparate leuke-
mogenic pathways and driver events.
2 |  MATERIALS AND METHODS
Detailed description of materials and methods is provided in 
the Appendix S1.
2.1 | Patient and reference samples
All available diagnostic bone marrow or peripheral 
blood samples of pediatric T‐ALL patients diagnosed be-
tween years 2008‐2013 (n = 65, age < 18 years) were re-
trieved from the NOPHO (Nordic Society of Paediatric 
Haematology and Oncology) Biobank (Uppsala, Sweden). 
Diagnosis was based on morphology, immunophenotyp-
ing, and cytogenetic analysis, and patients were treated 
according to the common NOPHO ALL 2008 protocol.11 
The regional and/or national ethics committees approved 
the study, and the patients and/or their guardians provided 
informed consent in compliance with the Declaration of 
Helsinki.
Publicly available methylation and gene expression data 
used for validation and as reference samples are listed in 
Table S1.
2.2 | Methylation array analysis
The methylation data for 65 T‐ALL samples and three re-
mission samples used in this study were generated using 
Human Methylation 450 K BeadChip arrays (Illumina, 
San Diego, CA, US) and have been deposited in the NCBI 
Gene Expression Omnibus (GEO) database (accession no. 
GSE69954; Table S1).9 The preprocessing, normalizing, 
and filtering of the data, as well as differential methylation 
and copy number variation analysis, are described in the 
Appendix S1.9
2.3 | CIMP classification, epigenetic 
(DNAm) age, and mitotic age estimation
The T‐ALL patients were previously CIMP classified using 
the 1293 CpG site CIMP panel.9 CIMP status is based on the 
percentage of methylated CpG sites (average β value >0.4) 
in the panel. Samples with more than 40% methylated CpG 
sites in the panel were classified as CIMP+, whereas samples 
having less than 40% methylated CpG sites were classified 
as CIMP−.9 The previously defined cutoff9 for CIMP status 
classification at 40% methylated CpGs sites within the CIMP 
panel was originally set in a separate T‐ALL cohort to re-
flect hierarchical sample clusters,10 with the most divergent 
prognosis.9
DNA methylation‐based models were used to predict epi-
genetic DNA methylation (DNAm) age12 and mitotic age13 of 
the 65 diagnostic T‐ALL samples, healthy children (n = 78) 
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(GSE36064),14 and sorted CD3+ T cells and CD34+ cells 
(GSE49618).15
2.4 | Telomere length measurement
Relative telomere length (RTL) was measured by the quan-
titative‐PCR method described previously,16 with minor 
modifications.17 Details of the method are described in the 
Appendix S1.
2.5 | RNA‐sequencing analysis
RNA sequencing was performed at the Science for Life 
Laboratory, Uppsala, Sweden, for 30 T‐ALL samples with 
available RNA. Sequencing libraries were constructed from 
a minimum of 600 ng RNA using the TruSeq Stranded Total 
RNA kit with Ribo‐Zero Gold treatment (Illumina). For each 
sample, paired‐end, strand‐specific reads with length of 125 
base pairs (bp) were generated on a HiSeq2500 (Illumina) 
instrument. Alignment, mapping, and downstream analysis 
including differential gene expression and fusion detection 
are described in the Appendix S1.
2.6 | Fusion transcript verification by 
polymerase chain reaction (PCR)
The STIL‐TAL1 fusions were confirmed by polymerase 
chain reaction (PCR) amplification of 64 T‐ALL samples 
with available DNA, using previously described primers for 
the most common TAL1 breakpoint region (taldb1).18 One 
of the samples was further analyzed using primers specific 
for an uncommon TAL1 breakpoint (taldb7).19 The PCRs 
included 50 ng DNA, 1X PCR Buffer II (Thermo Fisher 
Scientific, Waltham, MA), 0.2 mmol/L dNTP, 1.5 mmol/L 
MgCl2, 0.2 μmol/L primers (Eurofins, Ebersberg, 
Germany), and 1 unit of AmpliTaq Gold (Thermo Fisher 
Scientific).
2.7 | Targeted exome sequencing
The 65 diagnostic T‐ALL and three remission samples were 
screened for variations in epigenetic‐associated genes (Table 
S2) using Haloplex Target Enrichment System (Agilent 
Technologies, Santa Clara, CA), and the detailed method for 
variant calling is described in the Appendix S1.
2.8 | Statistical analysis
Statistical analysis was performed using SPSS v. 24 (SPSS 
Inc, Chicago, IL), the statistical package R v.3.4.0 (R Core 
Team), and SIMCA v.14.0 (Umetrics, Umeå, Sweden). All 
statistical tests for two sample hypotheses were two‐sided 
and considered significant if the P‐value (P) was <0.05. A 
full description of the statistical tests used is presented in the 
Appendix S1.
The gene set enrichment analysis (GSEA v.3.0)20,21 of 
differentially expressed genes used the 13 gene cluster signa-
tures obtained from Soulier et al.6
3 |  RESULTS
3.1 | DNA methylation analysis defines 
distinct epigenetic T‐ALL subgroups
Among the 65 diagnostic T‐ALL samples in the study, 
25 were classified as CIMP− and 40 were classified as 
CIMP+ (Table 1). The promoter methylation levels at CpG 
sites, up to 1500 bp upstream of the transcription start sites 
(TSSs) of all genes represented on the HumMeth450K 
array (n = 19 298) after filtering, were investigated in T‐
ALL and reference samples (Figure 1A, Table 1). Both 
T‐ALL subgroups had higher mean promoter methylation 
than the normal sorted CD34+ and CD3+ T cells, and the 
CIMP+ subgroup showed significantly (P < 0.001) higher 
mean promoter methylation levels (0.47 ± 0.02) than the 
CIMP− subgroup (0.41 ± 0.01) (Table 1; Figure 1A). 
Differential methylation analysis revealed 12 063 differ-
entially methylated CpG sites (DM‐CpG) in 2254 genes 
between the CIMP subgroups (Figure 1B). The inclusion 
of normal sorted immature CD34+ cells, mature CD3+ 
T cells, and five whole blood samples of healthy chil-
dren in the heatmap showed that the DM‐CpG sites were 
dominated by de novo‐methylated CpG sites in the CIMP+ 
subgroup. Furthermore, the CIMP− samples exhibited 
methylation profiles more similar to normal cells (Figure 
1B), irrespective of cell differentiation stage. The methyla-
tion levels of the DM‐CpGs were not associated with copy 
number variations as the average beta of the DM‐CpGs did 
not differ substantially between regions with gains or dele-
tions (Figure 1B; Figure S1).
Using normal sorted CD34+ cells as a reference, the num-
ber of hyper‐ and hypomethylated CpG sites were calculated 
for each T‐ALL sample (Table 1). There was a strong correla-
tion between the total number of hypermethylated CpG sites 
in the array and the percentage of methylated CpGs within 
the CIMP panel (R2 = 0.91, P < 0.001) (Table 1; Figure 
S2A). In contrast, the number of hypomethylated CpG sites 
correlated weakly with CIMP status (R2 = 0.11, P = 0.007) 
(Table 1; Figure S2B).
The hypermethylated CpG sites were enriched in CpG 
islands and promoter regions for both CIMP subgroups. 
However, CIMP+ samples displayed a significantly higher 
proportion of hypermethylated CpGs in these regions com-
pared to the CIMP− samples, whereas the CIMP− samples 
were more frequently hypermethylated outside CpG islands 
and in gene body regions (Table 1; Figure S2C,D).
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3.2 | Differential replicative history of 
CIMP subgroups
Accumulated DNA methylation alterations are known to be 
associated with cell proliferation.22,23 The proliferative his-
tory of T‐ALL samples, as well as control samples, was in-
vestigated using DNA methylation‐based models to predict 
mitotic age13 and epigenetic DNA methylation (DNAm) 
age,12 which were then correlated with the patients’ chrono-
logical age and CIMP status. As expected, the predicted mi-
totic age was higher in the leukemic T‐ALL samples than the 
sorted CD3+ T cells and CD34+ cells (Figure 1C). However, 
the CIMP+ subgroup had a significantly older mitotic age 
than the CIMP− subgroup (0.64 ± 0.11 vs 0.27 ± 0.07, 
P < 0.001) (Table 1; Figure 1C).
Similarly, the predicted DNAm age was higher in leu-
kemic cells than normal healthy blood cells from chil-
dren (n = 78) (Figure 1D) and the CIMP+ subgroup was 
estimated epigenetically older than the CIMP− subgroup 
(152.8 ± 49.3 years vs 17.8 ± 31.3 years, P < 0.001) 
(Table 1; Figure 1D). As in healthy children (R2 = 0.86, 
P < 0.001), DNAm age was correlated with chronological 
age in CIMP− samples (R2 = 0.44, P < 0.001), but this 
correlation was not seen in CIMP+ samples (R2 = 0.01, 
P = 0.53) (Figure 1D).
A longer proliferation history and an older epigenetic 
age of the CIMP+ subgroup were further supported by sig-
nificantly shorter relative telomere length (RTL) than the 
CIMP− group (0.85 ± 0.46 in CIMP+ vs 1.13 ± 0.77 in 
CIMP−, P = 0.015) (Table 1).
3.3 | Differential transcriptomic 
analysis of the CIMP subgroups
To explore the transcriptome and the subsequent functional 
differences between the CIMP subgroups, we performed 
T A B L E  1  Characteristics of the 65 CIMP classified pediatric T‐ALL samples
CIMP− CIMP+ P value
Number of samples 25 40
Mean promoter methylation level at TSS of all genes 
(mean, standard deviation)
0.41 (±0.01) 0.47 (±0.02) <0.001a
No. of hypermethylated CpG sites (mean, standard 
deviation)
19 557 (±5992) 49 692 (±11 364) <0.001b
No. of hypomethylated CpG sites (mean, standard 
deviation)
5160 (±2013) 3709 (±1772) 0.003a
Enrichment of hypermethylated CpGs in different genomic regions (median, standard deviation)
TSS1500 1.11 (±0.04) 1.12 (±0.05) nsc
TSS200 0.98 (±0.09) 1.15 (±0.06) <0.001c
5’UTR 1.02 (±0.06) 1.11 (±0.05) <0.001c
1st Exon 1.28 (±0.19) 1.58 (±0.08) <0.001c
Gene Body 0.89 (±0.03) 0.83 (±0.03) <0.001c
3’UTR 0.65 (±0.08) 0.50 (±0.03) <0.001c
Intergenic 1.10 (±0.04) 1.05 (±0.04) <0.001c
Enrichment of hypermethylated CpGs in different CpG island regions (median, standard deviation)
Island 1.32 (±0.19) 1.77 (±0.11) <0.001c
Shelf 0.42 (±0.07) 0.27 (±0.04) <0.001c
Shore 1.30 (±0.1) 1.19 (±0.06) <0.001c
Open Sea 0.66 (±0.1) 0.37 (±0.06) <0.001c
Chronological age/years (mean, standard deviation) 7.7 (±5.4) 8.6 (±4.8) nsb
Mitotic aged (mean, standard deviation) 0.27 (±0.07) 0.64 (±0.11) <0.001b
DNAm agee(median, standard deviation) 17.8 (±31.3) 152.8 (±49.3) <0.001c
Relative telomere length (median, standard deviation) 1.13 (±0.77) 0.85 (±0.46) 0.015c
ns, not significant (P value >0.05); TSS, transcription start sites
aIndependent samples t test (equal variances assumed), 
bIndependent samples t test (unequal variances assumed), 
cMann‐Whitney U test. 
dAccording to Yang et al 2016. 
eAccording to Horvath 2013. 
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RNA sequencing of 30 T‐ALL samples (12 CIMP− and 
18 CIMP+). An average of 76 million (m) reads (range 
56.7‐131.9 m) was generated with 97.9% of the reads map-
ping to the reference genome.
Differential gene expression analysis identified 764 
significantly differentially expressed genes (DEGs) out of 
which 216 genes had a higher expression in CIMP− sub-
group (log2 fold change (LFC) <−1) and 548 genes had 
a higher expression in the CIMP+ subgroup (LFC > 1) 
(Figure 2A‐C;Table S3). Enrichment analysis of the genes 
with a higher expression in the CIMP+ subgroup (clus-
ter B) (Figure 2B) revealed the enrichment of G‐protein 
signaling pathways, including regulation of cyclic‐AMP 
(cAMP), among the top most significant pathways (Table 
S4). The genes with a higher expression in CIMP− sub-
group (cluster A) were enriched in pathways associated 
with transcriptional regulation of granulocyte development 
and mTORC2 (mammalian target of rapamycin complex 2) 
signaling (Table S4).
3.4 | Epigenetic regulators and 
CIMP subgroups
Mutations in specific epigenetic regulators have been associ-
ated with T‐ALL.24 The CIMP subgroups (65 diagnostic T‐
ALL samples and three remission samples) were investigated 
for variations in genes involved in epigenetic regulation by 
targeted exome sequencing (Table S2). In addition to exome 
F I G U R E  1  Differential DNA methylation patterns within pediatric T‐ALL. (A) Mean methylation levels (average β‐values) of CpGs in 
promoter regions (0‐1500 bp) upstream of transcription start sites of all genes in the HumMeth450k array (n = 19 298) were compared between 
the T‐ALL CIMP subgroups, normal sorted CD34+ and CD3+ cells using one‐way ANOVA test. (B) The heatmap (to the left) shows the average 
β‐values of 12 063 differentially methylated CpG (DM‐CpG) sites (delta β > 0.4 or <−0.4) between CIMP subgroups, with each CpG site shown as 
individual rows. The 65 T‐ALL samples, as the columns, are sorted according to increasing CIMP methylation (range 9%‐98%) along with sorted 
CD3+ T cells,15 CD34+ cells,15 and five whole blood samples from healthy children.14 The heatmap to the right shows the number of samples 
that have deletions or gains in the corresponding DM‐CpG region. The color intensity represents the number of samples, ranging from white (no 
samples) to black (>6 samples), with copy number variations. (C) Predicted mitotic age (calculated according to Yang, et al 2016) in normal CD3+ 
T cells, CD34+ cells, and CIMP T‐ALL subgroups is compared (one‐way Welch's ANOVA test). (D) Predicted DNAm age (estimated according to 
Horvath, 2013) of CIMP subgroups (n = 25 CIMP− and n = 40 CIMP+ samples) and healthy children (n = 78, age range 1‐16 y) is correlated with 
chronological age. The Pearson correlation coefficient (R2) is given for each group
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sequencing, we examined gene expression in 30 diagnostic 
T‐ALL samples to investigate whether the CIMP classifica-
tion correlated with dysregulated epigenetic regulators.
The targeted sequencing generated an average of 1 m 
reads (range 0.3‐3.1 m reads), and 43 variations in 11 genes 
were retained after filtering (Figure S3A,B; Table S5). All 
identified variants were confirmed in samples analyzed by 
RNA sequencing by manually inspecting BAM files in IGV 
(except for the PHC2 gene that had no coverage). A majority 
of the identified variants were predicted as “benign,” and no 
F I G U R E  2  Differential transcriptomic analysis of CIMP T‐ALL subgroups. (A) The pipeline for identifying 764 differentially expressed 
genes (DEGs) between CIMP− (n = 12) and CIMP+ (n = 18) T‐ALL samples. Log2 fold change (LFC) was calculated using the CIMP− subgroup 
as reference. (B) Heatmap showing Min‐Max scaled regularized log transformed (rlog) counts of the 764 DEGs (rows). The samples (columns) are 
sorted by increasing CIMP methylation (range 11% to 98%). Unsupervised euclidean clustering separated the DEGs in two clusters. The cluster 
A genes (n = 216) had higher expression in CIMP− (LFC <−1) whereas the cluster B genes (n = 548) had a higher expression in CIMP+ (LFC 
>1) samples. (C) Volcano plot of the differential transcriptomic analysis is shown, with the top ten significant DEGs in each cluster, marked, and 
labeled
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correlation between variations in epigenetic regulators and 
CIMP methylation phenotype could be observed (Figure 
S3B; Table S5). Expression analysis showed variable expres-
sion levels of epigenetic‐associated genes within the T‐ALL 
samples, but no correlation with CIMP status (Figure S4) 
could be detected.
3.5 | CIMP status correlated with known T‐
ALL subtypes
Transcriptomic analysis of the CIMP subgroups identified a 
number of known T‐ALL drivers such as TAL1 (LFC −4.1), 
TLX3 (LFC 12.2), and NKX2‐1 (LFC 21.5) among the top 
most significant DEGs (Figure 2C) as well as HOXA9 (LFC 
4.6), HOXA10 (LFC 4.8), and MEF2C (LFC 2.4) implicated 
as differentially expressed (Table S3). The sample cluster-
ing based on the gene expression profiling of known T‐ALL 
drivers correlated with CIMP methylation status (Figure 3A). 
The TAL1 overexpression was associated with CIMP− sta-
tus, and the HOXA9/10 as well as the TLX1/2/3 clusters was 
restricted to the CIMP+ samples (Figure 3A). High TLX3 ex-
pression was seen in 9/18 CIMP+ samples but not in CIMP− 
samples (0/12) (Figure 3A). Since TLX1/2/3, NKX2‐1, and 
HOXA genes belong to the same ANTP homeobox gene 
F I G U R E  3  Transcriptional subtypes of T‐ALL and CIMP status. (A) The heatmap shows unsupervised clustering of 30 T‐ALL samples 
based on the gene expression (in rlog counts) of 11 transcription factors known to be overexpressed in T‐ALL. CIMP methylation percentage of the 
clustered samples is presented below the heatmap. (B) Gene expression (rlog counts) profile of the ANTP class of homeobox genes and cofactors is 
shown for the T‐ALL samples sorted by increasing CIMP methylation percentage (range 11%‐98%)
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family,25 we performed a comprehensive expression analy-
sis including all members of the gene family along with the 
known HOXA cofactors MEIS126 and PBX3 27 (Figure 3B). 
Specific members of the HOXA and NKL subclass had higher 
expression in the CIMP+ subgroup (Figure 3B; Table S3).
The association of CIMP subgroups with TAL1 and ho-
meobox gene expression profiles was further supported by 
gene set enrichment analysis (GSEA) of the identified 764 
DEGs in our study with the 13 T‐ALL gene expression clus-
ter signatures defined by Soulier et al6 (Table S6). Genes with 
F I G U R E  4  Fusion detection in pediatric T‐ALL. (A) The pipeline used for detection of fusion genes from RNA‐sequencing data by 
FusionCatcher is shown. (B) The heatmap shows the occurrence of identified gene fusions in relation to CIMP status in the 30 T‐ALL samples. The 
fusions marked with (*) are known recurrent translocations in T‐ALL. (C) Sashimi plots showing the junctions supporting the STIL‐TAL1 fusions 
identified in (B) in six CIMP− samples (green). A reference sample (CIMP+ sample) with no fusion detected is shown in red
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a higher expression among CIMP− samples (cluster A) were 
significantly enriched for genes in Soulier’s C2 (P < 0.001) 
and C3 (P < 0.001) clusters, both of which characterize TAL1 
expressing T‐ALL patients. Similarly, the genes with a higher 
expression in the CIMP+ samples (cluster B) correlated with 
the homeobox‐associated C8 (P = 0.02), C9 (P = 0.04), and 
C11 (P = 0.01) clusters (Table S6).
3.6 | STIL‐TAL1 fusions in 
CIMP− subgroup
The majority of oncogenes implicated in T‐ALL biology are 
activated by genomic alterations.3 We used FusionCatcher to 
identify translocations in the 30 T‐ALL samples that were 
analyzed by RNA sequencing (Figure 4A). After filter-
ing, 119 translocations remained, represented by 30 unique 
gene combinations (Figure 4A,B; Table S7). We identified 
genes with high expression in the transcriptome analysis that 
was associated with the identified translocations, including 
NKX2‐1‐TRA, TRB‐LYL1, and most notably STIL‐TAL1 
translocations (Figure 4B). Interestingly, the STIL‐TAL1 fu-
sions were found only in the CIMP− subgroup (6/12 CIMP− 
and 0/18 CIMP+ samples) (Figure 4B,C).
The presence of STIL‐TAL1 translocations in the 
CIMP− subgroup was verified by PCR, using primers18 
designed for the most commonly occurring TAL1 deletion 
breakpoint 1 (taldb1) and the STIL deletion breakpoint 1 
(stildb1). STIL‐TAL1 translocations were observed in 42% 
(10/24) of CIMP− samples compared with 5% (2/40) of 
CIMP+ samples (Figure S5A). All samples but one (X70) 
that were positive for the fusion by RNA sequencing were 
verified (Figure S5A). Upon visual inspection of the align-
ment data using IGV, X70 was found to carry a rare TAL1 
breakpoint, namely TAL1 deletion breakpoint 7 (taldb7), 
that was later verified by a different pair of PCR primers19 
(Figure S5B).
3.7 | Novel genes in T‐ALL biology
In addition to the TAL1 and ANTP homeobox gene fam-
ily members, several genes not previously associated 
with T‐ALL biology were identified among the top most 
significant DEGs between the CIMP subgroups, includ-
ing BEX1, PLXND1, PLCB4, and MYO18B (Figure 2C). 
The brain‐expressed X‐linked 1 (BEX1) gene, located on 
the X chromosome, had the lowest adjusted P‐value, with 
a higher expression in the CIMP− subgroup (LFC‐6.3). 
BEX2, another member of the BEX gene family, was also 
differentially expressed (LFC‐2.2) (Table S3). Since epige-
netic mechanisms regulate X chromosome inactivation in 
females, we analyzed whether BEX1 or BEX2 expression 
was associated with gender of the patients. The expression 
of both, BEX1 and BEX2, did not correlate with the gender 
of the patients (P = 0.93 and P = 0.53, respectively, Mann‐
Whitney U test).
In contrast to the BEX genes, the PLXND1 (Plexin D1), 
PLCB4 (Phospholipase C) genes had significantly higher 
expression in the CIMP+ subgroup (LFC 3.4 and LFC 5.8, 
respectively) (Figure 2C; Table S3). PLXND1 has previously 
been associated with intra‐thymic migration of thymocytes 
during T‐cell development,28 and both, PLXND1 and PLCB4, 
have been implicated in various cancers29,30 but not in T‐
ALL. The MYO18B (Myosin XVIIIB) gene, a tumor sup-
pressor gene associated with lung,31 ovarian,32 and colorectal 
cancer,33 was strongly expressed (LFC 7.5) in a set of CIMP+ 
cases (7/18) (Figure 2C).
3.8 | Validation of DEGs in a separate T‐
ALL cohort and normal stimulated T cells
In order to relate the expression levels of selected DEGs in 
the CIMP subgroups to normal cells, we used our previously 
published gene expression array data10 of a separate cohort of 
pediatric T‐ALL patient samples (11 CIMP− and 6 CIMP+) 
and normal stimulated T cells (n = 2). Despite the limited 
sample size, we observed that the TAL1, BEX1, and BEX2 
genes were weakly expressed in normal and CIMP+ sam-
ples but significantly upregulated in the CIMP− subgroup 
(Figure S6). Conversely, the PLXND1, PLCB4, HOXA9, 
HOXA10, TLX3, and NKX2‐1 genes had higher expression 
in the CIMP+ subgroup, compared to the normal T cells and 
CIMP− leukemias (Figure S6).
3.9 | Integrated promoter methylation and 
gene expression analysis for the DEGs
An integrated promoter methylation and gene expression 
analysis, including genes located on the X chromosome, were 
performed on the 30 T‐ALL samples with both transcriptomic 
and methylomic data. Promoter methylation data (TSS1500, 
TSS200, 5’UTR) were available for 746 of the 764 DEGs. A 
significant correlation between methylation and gene expres-
sion was observed in 281 of the DEGs, and 79% (n = 222) 
of these genes had negative correlations (Pearson correlation 
R range −0.36 to −0.93) (Table S3). Among the genes with 
the strongest negative correlation were TAL1 (R2 = 0.42), 
MYO18B (R2 = 0.86) and BEX1 (R2 = 0.67) (Figure 5A‐C; 
Table S3). Neither the HOXA9/10 genes nor the TLX3 gene 
expression was significantly correlated with promoter meth-
ylation (Table S3).
Methylation profiling at single CpG site resolution of 
the TAL1, BEX1, and MYO18B genes was performed in the 
CIMP− (n = 25) and CIMP+ (n = 40) samples, along with 
sorted CD3+ and CD34+ cells. (Figure 5D‐F). Analysis of 
the TAL1 regulon, including the neighboring PDZKIP1 and 
STIL genes, revealed that the TSS1500 promoter region and 
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F I G U R E  5  Promoter methylation of differentially expressed genes. Mean promoter methylation (TSS1500, TSS200 and 5’UTR) of (A) 
TAL1, (B) BEX1, and (C) MYO18B was correlated with gene expression (rlog counts) in the 30 T‐ALL samples using Pearson correlation (R2). 
DNA methylation (Avg. β value) of CpG sites in (D) the TAL1 regulon including the neighboring STIL and PDZKIP1 genes (E) BEX1 and (F) 
MYO18B was plotted for the CIMP+ (n = 40), CIMP− (n = 25) and normal sorted CD3+ T cells (n = 3) and CD34+ cells (n = 3). Each CpG site 
is colored according to the annotated genomic region, and the TAL1 breakpoint region is marked
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the intergenic region between TAL1 and its immediate 5´ 
neighbor STIL were methylated in the CIMP+ subgroup in 
contrast to CIMP− and reference samples (Figure 5D). This 
region of variable methylation between the CIMP subgroups 
encompassed the TAL1‐breakpoint region, frequently in-
volved in translocations (Figure 5D).
The methylation level of BEX1 was most variable in the 
TSS200 and 5’UTR promoter region, in which a number 
of CIMP− samples showed hypomethylation compared to 
CIMP+ and reference cells (Figure 5E).
The MYO18B gene promoter was methylated in the CIMP− 
subgroup, sorted CD3+ and CD34+ cells but was hypometh-
ylated (TSS200 and 5’UTR region) in a few CIMP+ samples 
that showed increased gene expression (Figure 5C,F).
4 |  DISCUSSION
We have previously shown prognostic relevant subgroup-
ing of pediatric T‐ALL samples at diagnosis based on DNA 
methylation CIMP (CpG island methylator phenotype) sta-
tus. In this study, the biology behind T‐ALL DNA methyla-
tion subgroups has been investigated which was previously 
unknown. An integrated methylomic, genomic, and tran-
scriptomic analysis identified links between CIMP status 
and known oncogenic drivers in T‐ALL, suggestive of dif-
ferent routes for cellular transformation in the methylation 
subgroups.
DNA methylation alterations are known to accumulate 
with increasing population doublings,23 and we have pre-
viously observed overlapping hypermethylation patterns 
between immortalized T‐cell in vitro cultures and CIMP+ 
T‐ALL patient samples, suggesting the association between 
accumulation of methylation alterations and proliferative his-
tory.22 In the current study, analysis of predicted mitotic and 
epigenetic DNAm age and telomere length analysis further 
support that CIMP+ cells are epigenetically older than the 
CIMP− cells.
Mutations and altered gene expression of DNA methyl-
transferases and polycomb‐associated genes have been impli-
cated in T‐ALL biology.24 Although genetic variants in these 
genes were identified in some T‐ALL samples, an association 
between CIMP status and genomic or transcriptomic dysreg-
ulation of epigenetic regulators was not detected.
To further characterize the epigenetic subgroups, we 
performed an exploratory transcriptomic analysis of protein 
coding genes. We identified a considerable number of differ-
entially expressed genes as well as enriched signaling path-
ways between the CIMP subgroups. Interestingly, genes with 
a higher expression in the CIMP− subgroup were enriched in 
the mTOR signaling pathway which has been shown associ-
ated with increased leukemia‐propagating potential in indi-
vidual T‐ALL clones.34
Among the differentially expressed genes, previously 
known T‐ALL driver oncogenes, such as TAL1, TLX3, 
HOXA9, HOXA10, and NKX2‐1, were identified. These on-
cogenic transcription factors have been previously described 
as markers for T‐ALL subgrouping based on gene expression 
profiles.4-6,35
TAL1 is overexpressed in approximately 60% of T‐ALL 
cases, and among these cases, about 30% are known to ex-
hibit this phenotype due to a ~90 kb microdeletion that 
translocates the TAL1 gene with the promoter of the neigh-
boring STIL gene.36 We found that the CIMP− subgroup was 
strongly associated with increased TAL1 gene expression, 
and a higher frequency of STIL‐TAL1 fusions was observed 
within this group. TAL1 overexpression may also occur as 
a consequence of TAL1‐TCRA/D translocations (~5% of 
TAL1 expressing T‐ALL),37 or non‐coding microinsertions 
that generate super‐enhancers.38,39 In the 30 T‐ALL samples 
that were RNA‐sequenced, no TAL1‐TCRA/D transloca-
tions were observed, but this could be explained by ineffi-
cient alignment to the TCR regions in the RNA‐sequencing 
analysis. Not all CIMP− samples with high TAL1 expression 
had the STIL‐TAL1 fusion, reaffirming that TAL1 expression 
can be regulated by other mechanisms than translocations. 
One of these mechanisms could be epigenetics as shown 
earlier.40,41 A strong negative correlation between TAL1 pro-
moter methylation and gene expression was observed in this 
study, corroborating similar findings by us and others.10,42,43 
Interestingly, the high‐resolution methylation analysis al-
lowed detailed analysis of the TAL1 regulon and showed that 
the variable methylated region between CIMP subgroups en-
compasses the TAL1 breakpoint region for the STIL‐TAL1 
fusion. The CIMP− samples showed low methylation in 
the breakpoint region as compared to the CIMP+ subgroup 
which could explain the higher frequency of STIL‐TAL1 
fusions in the CIMP− subgroup. A link between low meth-
ylation and high frequency of STIL‐TAL1 translocation has 
been previously observed.44,45
The CIMP+ group was overrepresented by a higher ex-
pression of homeobox genes, specifically the HOXA and 
NKL subclass of the ANTP gene family. The HOXA9 and 
HOXA10 genes belong to the HOXA subclass of the ANTP 
family, which also includes the NK‐like subclass compris-
ing of NKX‐ and TLX‐genes.25 The mechanisms leading to 
the overexpression of these genes in the CIMP+ could not 
be determined except for the translocation of NKX2‐1‐TRC 
found in one CIMP+ sample that overexpressed NKX2‐1. 
Gene expression of HOXA9, HOXA10, TLX1, TLX2, TLX3, 
and NKX2‐1 did not correlate with promoter methylation, 
and it remains to be evaluated if the differential expression of 
the homeobox genes contributed to the divergent methylation 
profiles of the CIMP subgroups.
It has previously been shown that T‐ALL samples can 
be classified based on gene expression signatures driven 
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by transcription factor oncogenes and that these signatures 
correlate with transcriptional profiles of different stages of 
thymocyte development.5 TAL1 expressing T‐ALL samples 
have previously been shown to correlate with the late cortical 
and mature stage of T‐cell development whereas homeobox 
gene‐driven T‐ALLs were associated with the early cortical, 
double‐negative stages of T‐cell development.5 Despite the 
correlation of TAL1 and homeobox gene expression with 
CIMP classification, the CIMP subgroups did not correlate 
with the immunophenotype stage based on EGIL (European 
Group for the Immunological characterization of leukemias) 
classification.9 Future methylome and transcriptome analysis 
of sorted T cells from different stages of thymocyte devel-
opment may help elucidate the relationship between CIMP 
subgroupings and T‐cell differentiation.
The transcriptome analysis also identified differentially 
expressed genes between CIMP subgroups that had not 
been previously linked to T‐ALL biology, including BEX1, 
PLXND1, PLCB4, and MYO18B. The MYO18B gene has 
previously been described as a tumor suppressor gene whose 
expression was shown to be regulated by epigenetic mecha-
nisms in lung,31 ovarian,32 and colorectal cancers.33 Its rel-
evance for hematological malignancies is largely unknown 
but we have shown dysregulated gene expression of MYO18B 
in pediatric T‐ALL. In contrast to lung cancer,31 where pro-
moter hypermethylation of this gene in transformed cells was 
associated with gene silencing, we observed that promoter 
hypomethylation of MYO18B was associated with upregu-
lation of gene expression in a set of CIMP+ T‐ALL sam-
ples. Further investigations are, however, needed to evaluate 
whether this gene has an oncogenic or a tumor suppressor 
role in T‐ALL.
The PLXND1 gene has been implicated in intra‐thymic 
migration of thymocytes during T‐cell development, is a 
transcriptional target of the T‐ALL‐associated NOTCH sig-
naling pathway, and has been found to be upregulated in 
prostate cancer.28,29 PLCB4 has also been associated with 
various cancers such as gastrointestinal tumors46 and mel-
anoma.30 The BEX family genes, namely BEX1 and BEX2, 
were significantly upregulated in the CIMP− subgroup, and 
we showed a negative correlation of promoter DNA methyl-
ation with gene expression for both BEX genes in the T‐ALL 
samples. The expression of BEX1 and BEX2 has been previ-
ously shown to be regulated by epigenetic mechanisms in-
cluding promoter methylation.47 Both BEX1 and BEX2 have 
been described as tumor suppressor genes in glioma47 and 
acute myeloid leukemia (AML).48,49 However, the function 
and prognostic relevance of these genes in T‐ALL biology 
remain to be evaluated.
Altogether, our findings suggest the existence of differ-
ent routes for leukemogenic transformation in the CIMP− 
and CIMP+ subgroups of T‐ALL, indicated by their 
distinct methylomic and transcriptomic patterns. We have 
previously shown that CIMP classification at diagnosis 
can improve risk stratification of MRD‐defined risk cate-
gories after induction therapy.9 Summarizing the existing 
findings from clinical, genetic, epigenetic, and transcrip-
tomic analysis of the CIMP subgroups, in this and our pre-
vious studies9,10,22 reveal that CIMP− patients have a worse 
prognosis, with high white blood cell counts at diagnosis, 
younger predicted epigenetic and mitotic age, and higher 
TAL1 expression. It can be extrapolated that the regulation 
of TAL1, either by promoter methylation or translocations, 
renders the prognosis of the CIMP− subgroup unfavorable. 
In a previous study, the presence of STIL‐TAL1 fusion in 
T‐ALL resulted in a significantly inferior overall survival 
as well as relapse‐free survival.50 Furthermore, in the same 
study, STIL‐TAL1+ T‐ALL had a significantly shorter 
time of disease onset in murine models which could ex-
plain the younger epigenetic and mitotic age as well as lon-
ger telomere length in the CIMP− subgroup. However, the 
impact of TAL1 on T‐ALL prognosis is still debatable as 
other studies report better outcome for TAL1 expressing T‐
ALL.51 The higher expression of mTOR signaling pathway 
in CIMP− subgroup can also be speculated to contribute 
to the worse prognosis of this particular group since previ-
ous studies have shown the association of activated mTOR 
pathway with poor clinical outcome,52,53 owing to the role 
of PI3K/Akt/mTOR pathway in the survival of drug‐resis-
tant leukemia‐initiating cells.54
On the other hand, the CIMP+ subgroup have a better 
prognosis, are epigenetically and mitotically older, with hy-
permethylation in promoter regions of polycomb target genes, 
and have a higher expression of homeobox genes. Especially 
for CIMP+ classified patients, demethylating therapeutic 
agents, such as decitabine and azacitidine, have the potential 
to be included in ALL treatment protocols. Decitabine was 
well tolerated in a clinical trial phase 1 study in 39 relapse 
ALL patients.55
Recently, it was also shown that classification based on 
gene mutations (NOTCH1, FBXW7, PTEN, and Ras) com-
bined with MRD and WBC status improves risk stratification 
of pediatric T‐ALL patients.56 The next step will be to com-
bine the mutational classification with CIMP subgrouping in 
larger cohorts, to evaluate the interplay of these prognostic 
biomarkers and their individual and combined potential to 
improve therapy stratification of T‐ALL. Functional analysis 
of the novel genes in T‐ALL biology identified in this study 
(BEX1, PLXND1, PLCB4, and MYO18B) will further evalu-
ate their role in T‐ALL pathogenesis and therapy response.
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